Global investment giant KKR has agreed to acquire 100% of Medicover India for approximately €1.2 billion. The deal includes 24 hospitals and a fresh capital infusion of up to ₹4,000 crore to fund growth and debt reduction. The transaction, expected to close in Q4 2026, allows the Swedish parent firm to exit the Indian market and refocus on Europe.
Global investment firm KKR has signed a definitive agreement to acquire 100% of Medicover India, the hospital chain of Sweden-based Medicover AB. The transaction is valued at approximately €1.2 billion (roughly $1.4 billion). This move marks a significant reentry for KKR into the Indian hospital sector, following its past involvement with other healthcare assets in the country.
The acquisition involves a network of 24 multi-specialty hospitals with a capacity of approximately 4,800 beds, primarily located in South and West India. The deal is structured not only as a buyout but also as a growth accelerator. KKR plans to inject ₹3,000 to ₹4,000 crore of primary capital into the business. This fresh funding is earmarked for infrastructure upgrades, expanding the facility network, and debt repayment, which is a common focus in capital-intensive hospital chains.
For the Swedish parent company, Medicover AB, this sale represents a strategic pivot. The firm entered the Indian market in 2017 but has now decided to exit to concentrate resources on its core European markets, including Germany, Poland, and Romania. For the 12-month period ending June 30, 2026, Medicover India reported revenue of €220.5 million and an EBITDA of €26.1 million.
While the deal highlights strong private equity appetite for Indian healthcare, investors should note the complexities of this sector. The Indian hospital market is highly competitive and capital-intensive, requiring constant investment to maintain service standards and facility quality. A key operational risk lies in the integration and management of such a large, multi-site network. The ability of the new management to effectively deploy the planned capital infusion to improve profit margins and operational efficiency will be a vital monitorable.
The completion of the transaction is subject to customary regulatory approvals and is anticipated by the fourth quarter of 2026. Investors should track future updates regarding regulatory clearances and management commentary on how the company plans to utilize the newly injected capital to compete with established domestic healthcare players.